Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Cancers · 08.07.2026 · 18 (14) · 2194
DOI: 10.3390/cancers18142194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 08.07.2026. Verfasst von Lin Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai 200032, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Clinical Research Center, Shanghai Clinical Research Center for Radiotherapy.
Abstract (Originalsprache)
Background
Circulating tumor HPV DNA (ctHPV DNA) has shown clinical value in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), but its relationship with tumor burden and its role in prognosis, especially when combined with clinicoradiological factors, remain to be further defined.
Methods
We analyzed 103 patients with HPV-positive OPSCC enrolled in an observational biomarker study, most of whom received induction chemotherapy or chemoimmunotherapy followed by definitive radiotherapy. Blood samples were collected at pretreatment, post-radiotherapy, and follow-up time points, and ctHPV DNA levels were quantified using droplet digital PCR. Baseline clinicoradiological parameters from contrast-enhanced MR or CT and 18F-FDG PET/CT were analyzed for their association with ctHPV DNA levels and clinical outcomes.
Results
Baseline ctHPV DNA correlated with primary tumor volume (VT), nodal volume (VN), total tumor volume (VT+N), and the number of involved primary tumor sites and lymph node regions, particularly LN-related features. VT and maximum LN diameter were independent predictors of baseline ctHPV DNA. Detectable follow-up ctHPV DNA was associated with inferior progression-free survival but showed low sensitivity and positive predictive value for relapse detection. Integrative stratification using baseline ctHPV DNA and VT+N identified a potential high-risk subgroup with high tumor volume but paradoxically low ctHPV DNA (VOLhighDNAlow). Exploratory RNA-seq analysis was performed to investigate potential biological features underlying this discordance, and a seven-gene signature associated with PFS was identified.
Conclusions
These findings suggest that baseline ctHPV DNA reflects tumor burden and may provide additional information for upfront risk stratification in HPV-positive OPSCC, warranting further validation in larger prospective cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, China.
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.
ORCID-Profile: Lin Zhu, Xueguan Lu
Förderung
- National Natural Science Foundation of China
- Shanghai Clinical Research Center
- Shanghai Clinical Research Center for Radiotherapy
Zitieren
APA
Zhu, L., Shen, C., Qian, W., Liu, P., Xu, T., Liu, H., Zhou, X., & Lu, X. (2026). Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Cancers, 18(14), 2194. https://doi.org/10.3390/cancers18142194
Vancouver
Zhu L, Shen C, Qian W, Liu P, Xu T, Liu H, et al. Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Cancers. 2026;18(14):2194. doi:10.3390/cancers18142194
BibTeX
@article{Zhu2026,
author = {Zhu, Lin and Shen, Chunying and Qian, Wei and Liu, Peiyao and Xu, Tingting and Liu, Huijuan and Zhou, Xin and Lu, Xueguan},
title = {Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2194},
doi = {10.3390/cancers18142194}
}
EUVIMED